🟢 Teva Pharma is trading 6% up today after FDA approval of WELTRUZA

Teva Pharma is trading at $41.56, up 5.90%, after the FDA approved WELTRUZA, Teva’s once-monthly injectable olanzapine for adults with schizophrenia.

• Teva expects U.S. availability in the coming weeks.
• The approval is a clear company-specific catalyst for the October 9, 2026 rise.
• Recent closes were comparatively steady: $39.25 on October 8 and $39.18 on October 7.